|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
    |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
"We have not registered the resale of a sufficient number of shares of
common stock in this offering to fully draw down the $50 million
available under the Equity Line of Credit. At an assumed offering price
of $0.08 per share, we would only be able to draw a total gross amount
of $7,657,008 under the Equity Line of Credit using all of the 95,712,595 shares being registered in this offering. Based on an assumed offering price of $0.08 per share, we would need to issue 625,000,000 shares of common stock to draw the entire $50 million available under the Equity Line of Credit. If the price of our common stock decreased to $0.04 per share we would need 1,250,000,000 shares of common stock to draw the entire $50 million available under the Equity Line of Credit. Based on the 544,591,722 shares of stock currently outstanding, we do not have sufficient authorized shares of common stock to draw down the entire $50 million available under the Equity Line of Credit at an assumed stock price of either $0.08 or $0.04 per share. To increase the number of authorized shares of our common stock, we would need to obtain stockholder approval. We are uncertain that we could obtain this approval based on the dilutive effect of the issuance of shares under the Equity Line of Credit. Additionally, we would need to file another registration statement to cover any shares under the Equity Line of Credit other than the 95,712,595 being registered in this registration statement." IAG |
|
At the beginning of the article, it states in the Company Brief:
(Nasdaq:ADVR;www.adviral.com) Are we on the Nasdaq now, or was this a typo? Either way, the entire article is fantastic news. They're currently in discussions with Pharma's, and talk of Fast Track and Phase II/III trials. On the markert within 4yrs.(that's not taking into consideration getting Fast Tracked) Great things are going to happen in the future. I'm loading up on this one. |
|
A solution for body wasting Updated: 1/7/2004 By: Emily Schmitz Eric Blanchette takes human growth hormone to fight body wasting syndrome. People who are HIV-positive are living longer today than they did just a decade ago. Research shows people taking the highly active anti-retroviral treatment, or HAART therapy, live an average of 11 years after they're diagnosed. Eric Blanchette is beating those odds. He was diagnosed with HIV 23 years ago. He takes four medications a day. But living this long with the disease and taking the very medications that keep him alive come with a cost. He suffers from a condition called body wasting syndrome where his body starts to metabolize his own body fat and protein. "I also started noticing in my extremities that I was able to see my veins and things that I didn't see before," Blanchette said. Dr. David Wright's been treating Eric for the last five years. "What you really want to see if an increase of lean body mass or an increase in protein stores," Wright said. The solution for Blanchette was taking hormones. "I went on human growth hormone which was very successful. The results were dramatic," he said. Human growth hormone is the standard treatment for body wasting. But patients can only stay on that for about 12 weeks. There are some side effects and it costs more than $20,000 for each course of treatment. Researchers in New York have high hopes on a more effective and less expensive treatment for body wasting. They're studying a drug called AVR-118. It's about a tenth of the cost of human growth hormones. And initial studies are showing great promise. "In a non-toxic way, it can help patients get through their treatment and gain weight and improve their quality of life," said Dr. James D'Olimpio, a palliative medicine specialist. Blanchette is optimistic about the research in New York. But he said his current side effects are a small price to pay to be alive. www.news8austin.com |
|
"Researchers in New York have high hopes on a more effective and less
expensive treatment for body wasting. They're studying a drug called
AVR-118. It's about a tenth of the cost of human growth hormones. And
initial studies are showing great promise. "In a non-toxic way, it can help patients get through their treatment and gain weight and improve their quality of life," said Dr. James D'Olimpio, a palliative medicine specialist." http://ragingbull.lycos.com/mboard/boards.cgi?board=ADVR&read=135010 |
|
"They're studying a drug called AVR118." http://news8austin.com/content/living/health_beat/?SecID=169&ArID=94310 - - - - - |
the link from above is shown below.
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
No scan necessary, just cut and paste:: ----------------------------- 42 LEADERS POSTED WITH PERMISSION. COPYRIGHT © LEADERS An Interview with Eli Wilner, Chairman, and James T. D'Olimpio, M.D., Member, Scientific Advisory Board, and Spokesperson at Large, Advanced Viral Research Corp., Yonkers, New York Eli Wilner James T. D'Olimpio INTERVIEW A Life-Changing Drug? EDITORS? NOTE A past Bryant Fellow of the Metropolitan Museum of Art, Eli Wilner holds a B.A. from Brandeis University and an M.A. from Hunter College. Dr. James D'Olimpio, who is triple board certified in internal medicine, medical oncology, and hospice/palliative medicine, is also director of supportive oncology and the Palliative Care/Cancer Pain Service at North Shore University Hospital in Manhasset, New York, as well as an assistant professor at New York University's medical school. COMPANY BRIEF Headquartered in metropolitan New York, Advanced Viral Research Corp. (Nasdaq: ADVR; www.adviral.com) is a biopharmaceutical firm dedicated to improving people's lives by developing and bringing to market new effective therapies for viral and other diseases. Its primary
involvement at present is its peptide-nucleic acid AVR118, now
in clinical trials in Israel for the treatment of cachexia, or
body wasting, in patients with AIDS.You've reported quite a
remarkable breakthrough in the battle against AIDS. Please
elaborate. D'Olimpio: The group we've assembled is basically
trying to improve the quality of life of patients suffering from
HIV disease. Now, there are many elements to that, the most
important being the experience that patients endure while
they're receiving treatment. Treatments are much
Plus, it has
protection under a very strong patent, issued in March 2003 for
17 years. |
